Witryna17 mar 2024 · MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin … Witryna4 sty 2024 · MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2024. GlobeNewsWire • 02/18/21.
MNKD MannKind Corp. Stock Price & News - WSJ
Witryna20 maj 2024 · MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2024) To Be Held … [email protected]; SEZON ZIMOWY WINTER SEASON 1 października – 31 marca 1st October – 31st March środa – poniedziałek 09:00-16:00, czwartek – wtorek 09:00 … tempo scan tower jakarta
All News for MNKD : MannKind - Zacks.com
Witryna7 kwi 2024 · [email protected]; SEZON ZIMOWY WINTER SEASON 1 października – 31 marca 1st October – 31st March środa – poniedziałek 09:00-16:00, czwartek – … Witryna27 lut 2024 · Breaking News: MNKD latest news. - The Fly. The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Witryna23 lut 2024 · MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates. by Zacks Equity Research Published on November 08,2024. MannKind (MNKD) delivered … tempo scan saham